Mainz Biomed (MYNZ) Common Equity (2020 - 2025)
Historic Common Equity for Mainz Biomed (MYNZ) over the last 6 years, with Q2 2025 value amounting to $2.5 million.
- Mainz Biomed's Common Equity rose 16094.54% to $2.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.5 million, marking a year-over-year increase of 16094.54%. This contributed to the annual value of $6.0 million for FY2024, which is 8609.18% up from last year.
- Per Mainz Biomed's latest filing, its Common Equity stood at $2.5 million for Q2 2025, which was up 16094.54% from $6.0 million recorded in Q4 2024.
- In the past 5 years, Mainz Biomed's Common Equity ranged from a high of $23.8 million in Q2 2022 and a low of -$4.1 million during Q2 2024
- Moreover, its 5-year median value for Common Equity was $5.6 million (2023), whereas its average is $7.0 million.
- Its Common Equity has fluctuated over the past 5 years, first surged by 33202.73% in 2021, then crashed by 17993.8% in 2024.
- Over the past 5 years, Mainz Biomed's Common Equity (Quarter) stood at $6.4 million in 2021, then soared by 121.6% to $14.1 million in 2022, then plummeted by 76.95% to $3.2 million in 2023, then soared by 86.09% to $6.0 million in 2024, then tumbled by 58.28% to $2.5 million in 2025.
- Its Common Equity stands at $2.5 million for Q2 2025, versus $6.0 million for Q4 2024 and -$4.1 million for Q2 2024.